Published in Blood on January 25, 2005
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest (2010) 1.93
Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant (2009) 1.68
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol (2009) 1.64
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood (2010) 1.42
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood (2008) 1.25
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood (2009) 1.11
Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.07
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol (2009) 1.02
Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant (2013) 0.93
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. Biologics (2007) 0.93
Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol (2011) 0.93
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood (2014) 0.90
Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant (2009) 0.89
How to manage the transplant question in myelofibrosis. Blood Cancer J (2012) 0.89
Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Curr Opin Hematol (2009) 0.89
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant (2010) 0.87
Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant (2014) 0.81
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience. Mediterr J Hematol Infect Dis (2010) 0.79
Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms. Expert Rev Hematol (2010) 0.78
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Bone Marrow Transplant (2015) 0.78
Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT. Bone Marrow Transplant (2013) 0.77
Emerging drugs for myelofibrosis. Expert Opin Emerg Drugs (2012) 0.77
Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient. Leuk Res (2009) 0.76
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica (2016) 0.75
Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. Leuk Suppl (2012) 0.75
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. Biol Blood Marrow Transplant (2015) 0.75
Rational therapeutic options for patients with myeloproliferative neoplasms. Trans Am Clin Climatol Assoc (2011) 0.75
Primary myelofibrosis: current therapeutic options. Rev Bras Hematol Hemoter (2016) 0.75
Factors affecting prognosis in myelofibrosis. F1000 Med Rep (2009) 0.75
Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant (2016) 0.75
Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease. Hematol Oncol Clin North Am (2014) 0.75
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood (2006) 8.56
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
Essential role for Nix in autophagic maturation of erythroid cells. Nature (2008) 6.49
Genetic evidence for high-altitude adaptation in Tibet. Science (2010) 5.37
Characterization of clonogenic multiple myeloma cells. Blood (2003) 5.35
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood (2009) 4.22
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet (2002) 4.06
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood (2004) 4.01
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res (2008) 3.57
Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med (2012) 3.39
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis (2004) 3.06
Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2007) 3.03
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant (2005) 2.82
Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol (2002) 2.77
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 2.76
Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol (2007) 2.75
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology (2006) 2.72
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol (2008) 2.70
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood (2012) 2.65
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood (2013) 2.60
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood (2007) 2.53
Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood (2009) 2.51
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 2.45
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood (2008) 2.44
Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J Biol Chem (2006) 2.39
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2007) 2.33
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica (2004) 2.32
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol (2014) 2.26
High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood (2009) 2.25
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw (2009) 2.25
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol (2010) 2.25
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood (2006) 2.18
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol (2010) 2.16
Anemia in the elderly: time for new blood in old vessels? Arch Intern Med (2005) 2.14
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood (2011) 2.14
Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood (2004) 2.12
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood (2007) 2.09
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood (2008) 2.09
Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol (2009) 2.04
X-linked clonality testing: interpretation and limitations. Blood (2007) 2.04
Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia. Haematologica (2006) 2.04
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood (2004) 2.03
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood (2002) 2.03
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99
Congenital polycythemias/erythrocytoses. Haematologica (2005) 1.99
Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol (2007) 1.98
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica (2008) 1.97
Acute myeloid leukemia. J Natl Compr Canc Netw (2012) 1.96
Hematopoiesis is not clonal in healthy elderly women. Blood (2008) 1.95
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood (2011) 1.93
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res (2009) 1.92
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant (2012) 1.89
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol (2009) 1.88
Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood (2009) 1.86
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn (2003) 1.82
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica (2008) 1.80
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood (2009) 1.78
Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood (2003) 1.76
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood (2009) 1.74
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant (2007) 1.74
Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica (2006) 1.73
Cancer stem cells: are we missing the target? J Natl Cancer Inst (2004) 1.72
Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A (2004) 1.72
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res (2009) 1.71
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant (2008) 1.67
Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood (2002) 1.65
Polycythemia vera, the hematocrit, and blood-volume physiology. N Engl J Med (2012) 1.65
Helical tomotherapy targeting total bone marrow after total body irradiation for patients with relapsed acute leukemia undergoing an allogeneic stem cell transplant. Radiother Oncol (2011) 1.63
The paradox of response and survival in cancer therapeutics. Blood (2005) 1.63
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood (2009) 1.62
Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood (2007) 1.60
Genetic association analysis of chronic mountain sickness in an Andean high-altitude population. Haematologica (2005) 1.59